Portal vein chemotherapy for colorectal cancer: A meta-analysis of 4000 patients in 10 studies

Journal of the National Cancer Institute

Volumn 89, Issue 7, 1997, Pages 497-505

  Gray, R ^a   Clarke, M ^a   Collins, R ^a   Peto, R ^a   Piedbois, P ^a   Buyse, M ^a   Gray, B ^a   Gruenagel, H H ^a   De Rodriguez, M F ^a   Nitti, D ^a   Sahmoud, T ^a   Fielding, L P ^a   Fry, J ^a   Hittinger, R ^a   Beart, R ^a   Ingle, J ^a   Kahn, M ^a   O'Connell, M ^a   Rockette, H ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; HEPARIN; MITOMYCIN;

ARTICLE; CANCER MORTALITY; CANCER RECURRENCE; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; PORTAL VEIN BLOOD FLOW; TREATMENT OUTCOME;

EID: 0030985051     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/89.7.497     Document Type: Article

References (35)

1. Pisani P, Parkin DM, Ferlay J. Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden. Int J Cancer 1993;55:891-903.
2. Thomas WH, Larson RA, Wright HK, Cleveland JC. Analysis of 830 cases of rectal adenocarcinoma. 1. Progressively improved results of treatment. Conn Med 1969;33:569-70.
3. Ohman U. Colorectal carcinoma. A survey of 1345 cases 1950-1984. Acta Chir Scand 1985;151:675-9.
4. Peto R, Collins R, Gray R. Large-scale randomized evidence: large, simple trials and overviews of trials. J Clin Epidemiol 1995;48:23-40.
5. Buyse M, Zeleniuch-Jacquotte A, Chalmers TC. Adjuvant therapy of colorectal cancer. Why we still don't know. JAMA 1988;259:3571-8.
6. Gray R, James R, Mossman J, Stenning S. AXIS - a suitable case for treatment. UK Coordinating Committee on Cancer Research (UKCCCR) Colorectal Cancer Subcommittee [editorial]. Br J Cancer 1991;63:841-5.
7. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen CM, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995;122:321-6.
8. Zalcberg JR, Siderov J, Simes J on behalf of the Australasian Gastrointestinal Trials Group. The role of 5-fluorouracil dose in the adjuvant therapy of colorectal cancer. Ann Oncol 1996;7:41-6.
9. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 1995;345:939-44.
10. Wolmark N, Rockette H, Fisher B, Wickerham DL, Redmond C, Fisher ER, et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-03. J Clin Oncol 1993;11:1879-87.
11. Cedarmark BJ, Blumenson LE, Pickren JW, Holyoke DE, Elias EG. The significance of metastases to the adrenal glands in adenocarcinoma of the colon and rectum. Surg Gynecol Obstet 1977;144:537-46.
12. Goslin R, Steele G Jr, Zamcheck N, Mayer R, MacIntyre I. Factors influencing survival in patients with hepatic metastases from adenocarcinoma of the colon or rectum. Dis Colon Rectum 1982;25:749-54.
13. Holden WD, Dixon WJ. A study on the use of triethylenethiophosporamide as an adjuvant to surgery in the treatment of colorectal cancer. Cancer Chemother Rep 1962;16:129-34.
14. Morales F, Bell M, McDonald GO, Cole WH. The prophylactic treatment of cancer at the time of operation. Ann Surg 1957;146:588-95.
15. Taylor I, Machin D, Mullee M, Trotter G, Cooke T, West C. A randomized controlled trial of adjuvant portal vein cytotoxic perfusion in colorectal cancer. Br J Surg 1985;72:359-63.
16. Taylor I, Rowling J, West C. Adjuvant cytotoxic liver perfusion for colorectal cancer. Br J Surg 1979;66:833-7.
17. Beart RW Jr, Moertel CG, Wieand HS, Leigh JE, Windschitl HE, van Heerden JA, et al. Adjuvant therapy for resectable colorectal carcinoma with fluorouracil administered by portal vein infusion. A study of the Mayo Clinic and the North Central Cancer Treatment Group. Arch Surg 1990; 125:897-901.
18. Fielding LP, Hittinger R, Grace RH, Fry JS. Randomised controlled trial of adjuvant chemotherapy by portal-vein infusion after curative resection for colorectal adenocarcinoma. Lancet 1992;340:502-6.
19. Ryan J, Weiden P, Crowley J, Bloch K. Adjuvant portal vein infusion for colorectal cancer: a 3-arm randomized trial [abstract]. Proc ASCO 1988; 7:95.
20. Long-term results of single course of adjuvant intraportal chemotherapy for colorectal cancer. Swiss Group for Clinical Cancer Research (SAKK). Lancet 1995;345:349-53.
21. Wereldsma JC, Bruggink ED, Meijer WS, Roukema JA, van Putten WL. Adjuvant portal liver infusion in colorectal cancer with 5-fluorouracil/heparin versus urokinase versus control. Results of a prospective randomized clinical trial (Colorectal Adenocarcinoma Trial I). Cancer 1990;65: 425-32.
22. Wolmark N, Rockette H, Wickerham DL, Fisher B, Redmond C, Fisher ER, et al. Adjuvant therapy of Dukes' A, B, and C adenocarcinoma of the colon with portal-vein fluorouracil hepatic infusion: preliminary results of National Surgical Adjuvant Breast and Bowel Project Protocol C-02. J Clin Oncol 1990;8:1466-75.
23. Peto R, Pike M, Armitage P, Breslow NE, Cox DR, Howard SV, et al. Design and analysis of randomised clinical trials requiring prolonged observation of each patient. I: introduction and design. Br J Cancer 1976;34: 585-612.
24. Buyse M. Meta-analyses, use and misuse [letter]. J Clin Oncol 1993;11: 382.
25. Clarke MJ, Stewart LA. Obtaining data from randomized controlled trials: how much do we need for reliable and informative meta-analyses? BMJ 1994;309:1007-10.
26. Feinstein AR, Sosin DM, Wells CK. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med 1985;312:1604-8.
27. Collins R, Gray R, Godwin J, Peto R. Avoidance of large biases and large random errors in the assessment of moderate treatment effects: the need for systematic overviews. Stat Med 1987;6:245-54.
28. Stewart LA, Parmar MK. Meta-analysis of the literature or of individual patient data: is there a difference? Lancet 1993;341:418-22.
29. Schlag P, Saeger HD, Friedl P, et al. Perioperative adjuvant intraportal FUDR-chemotherapy does not influence prognosis of colon cancer patients [abstract]. In proceedings of the Sixth International Conference on the Adjuvant Therapy of Cancer, 1990.
30. Kimura O, Kurayoshi K, Hoshino K, Sugezawa A, Makino M, Kaibara N. Prophylactic portal infusion chemotherapy as adjuvant therapy for the prevention of metachronous liver metastasis in colorectal cancer. Surg Today 1995;25:211-6.
31. Dukes CE. The classification of cancer of the rectum. J Pathol 1932;35: 323-32.
32. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. Lancet 1992;339:71-85.
33. Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials. Early Breast Cancer Trialists' Collaborative Group. N Engl J Med 1995;333:1444-55.
34. Weiss L, Grundmann E, Torhorst J, Hartveit F, Moberg I, Eder M, et al. Haematogenous metastatic patterns in colonic carcinoma: an analysis of 1541 necropsies. J Pathol 1986;150:195-203.
35. Goldberg JA, Kerr DJ, Willmott N, McKillop JH, McArdle CS. Pharmacokinetics and pharmacodynamics of locoregional 5 fluorouracil (5FU) in advanced colorectal liver metastases. Br J Cancer 1988;57:186-9.